Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410865 | 0.95 | ALDH1A1 (0.41) | ALDH1A1CYP2E1CYP2A6CYP2B6CYP3A4 | |
| SCHEMBL10717926 | 0.89 | ALDH1A1 (0.33) | ALDH1A1HDAC1MAPK1 | |
| SCHEMBL9696786 | 0.88 | CYP1A2 (0.32) | CYP2A6 | |
| SCHEMBL10470838 | 0.85 | HSD17B1 (0.46) | ALDH1A1CYP2E1CYP2A6CYP2B6CYP3A4 | |
| SCHEMBL10472981 | 0.83 | APP (0.36) | ALDH1A1CYP2E1CYP2A6CYP2B6CYP3A4 | |
| SCHEMBL10472857 | 0.80 | CYP2A6 (0.30) | CYP2A6CYP2B6 | |
| SCHEMBL1416554 | 0.79 | HSD17B1 (0.47) | HSD17B1HSD17B2RAB9AMEN1KMT2A | |
| SCHEMBL1416520 | 0.79 | ALOX5 (0.40) | RAB9ATAAR1NPC1ESR2 | |
| SCHEMBL1416534 | 0.79 | ACHE (0.41) | ALDH1A1HSD17B1HSD17B2RAB9AMEN1 | |
| SCHEMBL1416461 | 0.76 | ACHE (0.36) | ALDH1A1CYP2C9CYP2C19HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392032-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | Arena Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| CN-117042558-A | Modification method of electron transport layer and organic solar cell prepared by modification method | 南开大学 | 2023-11-10 | — | — | CN | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023026185-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| CN-115353875-A | Fluorescent coding microsphere, preparation method and application thereof, and diagnostic kit | 苏州纳微生命科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-108601354-B | Use of active substances for controlling plant virus infections | 拜耳作物科学股份公司 | 2021-07-27 | — | — | CN | claimed |
| CN-109678900-B | Sulfanilamide derivative and preparation method and application thereof | 遵义医科大学 | 2021-05-11 | — | — | CN | claimed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| CN-1312799-A | Bispiperidines as antithrombotic agents | L LAB (FR) | 2001-09-12 | — | — | CN | claimed |
| EP-1080104-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-03-07 | — | — | EP | claimed |
| WO-2000061134-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-19 | — | — | WO | claimed |
| WO-2000055168-A1 | 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 2000-09-21 | — | — | WO | claimed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | claimed |
| US-4105663-A | HYPOTENSIVE, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-08-08 | — | — | US | claimed |
| US-4093628-A | HYPOTENSIVE AGENTS, BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-06-06 | — | — | US | claimed |
| US-4082772-A | HYPOTENSIVE AGENTS, B-ADRENERGIC BLOCKING AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-04-04 | — | — | US | claimed |
| US-4024156-A | Thiophene ethanolamines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-17 | — | — | US | claimed |
| US-3932389-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | ALDH1A1 700/4885CYP2E1 1190/4885CYP2A6 756/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | ALDH1A1 682/4885CYP2E1 1231/4885CYP2A6 788/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | ALDH1A1 682/4885CYP2E1 1231/4885CYP2A6 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.